If a subject cannot have a CT scan [e.g. allergy to contrast dye], an MRI should be performed. CT scan may be done within ±7 days of BV2. • Clinical assessment of tumor status using modified RECIST for assessment of response in MPM4 and irRC47 • Pulmonary function tests: VC, FVC and FEV 1 for Cohort 2 only • Optional core needle biopsy ; may be done anytime between CY6 (or final chemotherapy cycle) and prior to dosing at BV1 ( See Section 5.3) Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 43 5.2.2.5 Antibiotic Administration To eliminate any potentially residual CRS -207, subjects will be administered antibiotics after PV2 (and prior to receiving pemetrexed/cisplatin) and at the EOT visit and prior to receiving subsequent cancer -related (non -study) therapy. Subjects with a central line port will receive 1 dose [2 mg ampicillin or 3 -5 mg/kg trimethoprim/ sulfamethoxazole (in penicillin -allergic subjects)] of IV antibiotics through the port, followed by 6 days of oral antibiotics [amoxicillin or trimethoprim/sulfamethoxazole (in penicillin -allergic subjects)]; all other subjects will receive a 7 -day course of oral amoxicillin or trimethoprim/sulfamethoxazole (in penicillin -allergic subjects). Site personnel will contact the subject by telephone to facilitate compliance with antibiotic treatment; subjects will be required to record self -administration of antibiotics in a diary. If infection with CRS -207 is confirmed or suspected after more than 7 days post - infusion, IV antibiotics (see below) should be initiated as soon as possibl e and follow- up cultures obtained periodically to confirm absence/clearance of any CRS -207 infection. The Medical Monitor should be consulted regarding continuation of study drug treatment and treatment of suspected or confirmed infection. Consult the package inserts for amoxicillin, trimethoprim, and sulfamethoxazole for product information on dosage and administration, contraindications, warnings/precautions, adverse reactions, and drug interactions. 5.2.2.5.1 Antibiotic Treatment for CRS -207 Infection The recommended antibiotic regimen for suspected or confirmed CRS -207 infection after more than 7 days post -infusion is IV administration of ampicillin (or trimethoprim/sulfamethoxazole in penicillin -allergic subjects) plus gentamicin. Initial doses of ampicillin should be approximately 12 g/day (or per drug label) divided (3- 4 grams per dose every 3 to 4 hours), with gentamicin 3 mg/kg (or per drug label) daily in divided doses every 8 hours (with adjustments according to renal function and serum levels of gentamicin). In penicillin -allergic subjects, initial IV doses of trimethoprim/sulfamethoxazole should be 15 to 20 mg/kg/day (or per drug label) (based on trimethoprim component) divided 4 times Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 44 per day, with gentamicin 3 mg/kg daily in divided doses every 8 hours (with adjustments according to renal function and serum levels of gentamicin). For those individuals who receive IV antibiotics, the course of therapy is anticipated to be greater than or equal to 14 days, depending on clinical course.